Adaptive Biotechnologies (United States)
- World rank, all time
- #11,333 of 42,892
- Rank in United States
- #2,483 of 8,685
- Research works
- 170 ▼ 6% vs 2013–17
- Citations
- 7.2k 42.5 per fractional work
- Top-10% rate
- 22.0% record average 16.5%
- Open access
- 57% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Neuroscience, 8.5×. Every wedge is a field page.
- Neuroscience 8.5×
- Immunology and Microbiology 6.4×
- Medicine 2.9×
- Biochemistry, Genetics and Molecular Biology 2.3×
- Veterinary 2.0×
- Agricultural and Biological Sciences 0.7×
- Earth and Planetary Sciences 0.6×
- Energy 0.5×
- Materials Science 0.5×
- Psychology 0.3×
- Health Professions 0.3×
- Decision Sciences 0.2×
- Environmental Science 0.2×
- Physics and Astronomy 0.1×
- Economics, Econometrics and Finance 0.1×
- Computer Science 0.1×
- Engineering 0.1×
Who are the top researchers at Adaptive Biotechnologies (United States)?
Ranked on the composite score, Harlan Robins, Ryan Emerson and Catherine Sanders lead among researchers whose main affiliation is Adaptive Biotechnologies (United States).
- 1 Harlan Robins United States · #15,000 worldwide 717 citations · 51 works
- 2 Ryan Emerson United States · #30,861 worldwide 976 citations · 34 works
- 3 Catherine Sanders United States · #194,081 worldwide 277 citations · 18 works
- 4 Marissa Vignali United States · #224,619 worldwide 268 citations · 17 works
- 5 Rachel Gittelman United States · #1,182,567 worldwide 51 citations · 24 works
Which keywords describe research at Adaptive Biotechnologies (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Rituximab, Lymphoma, Pandemic, SARS-CoV-2, Classification, ACE2 Receptor, PET Imaging and Genetic Pathogenesis.
- Synchronization
- Glycosylation
- Cognitive Functions
- Clinical Characteristics
- Cancer Genomics
- EEG Analysis
- Chimeric Antigen Receptor
- Therapeutic Targets
- Chronic Lymphocytic Leukemia
- spike protein
- Vaccine
- Coronavirus
- International Myeloma Working Group
- Staging System
- Immunity
- Prognostic Factors
- Genetic Pathogenesis
- Classification
- SARS-CoV-2
- Lymphoma
- Rituximab
- Pandemic
- ACE2 Receptor
- PET Imaging
- Molecular Profiling
- Minimal Residual Disease
- Cancer Immunotherapy
- Diagnosis Criteria
- Mutation
- Immunotherapy
- antibody
- Antigen Presentation
- Genomic Aberrations
- CAR T Cells
- Brain-Computer Interfaces
- Immune Response
- Mutational Signatures
- Thrombosis
- Cortical Networks
- Neuronal Oscillations
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Rituximab5▲ 85×2 topics
- Lymphoma5▲ 78×2 topics
- Pandemic4▲ 8.9×5 topics
- SARS-CoV-24▲ 27×4 topics
- ACE2 Receptor3▲ 35×2 topics
- Classification3▲ 19×3 topics
- PET Imaging3▲ 50×2 topics
- Genetic Pathogenesis3▲ 154×1 topic
- Molecular Profiling3▲ 84×1 topic
- Prognostic Factors3▲ 19×5 topics
- Minimal Residual Disease3▲ 118×2 topics
- Immunity3▲ 18×2 topics
- Cancer Immunotherapy3▲ 43×3 topics
- Staging System2▲ 103×2 topics
- Diagnosis Criteria2▲ 173×1 topic
- International Myeloma Working Group2▲ 173×1 topic
- Mutation2▲ 30×3 topics
- Coronavirus2▲ 26×2 topics
- Immunotherapy2▲ 7.8×5 topics
- Vaccine2▲ 14×2 topics
- antibody2▲ 48×1 topic
- spike protein2▲ 48×1 topic
- Antigen Presentation2▲ 53×2 topics
- Chronic Lymphocytic Leukemia2▲ 99×1 topic
- Genomic Aberrations2▲ 99×1 topic
- Therapeutic Targets2▲ 30×2 topics
- CAR T Cells2▲ 58×1 topic
- Chimeric Antigen Receptor2▲ 58×1 topic
- Brain-Computer Interfaces2▲ 40×1 topic
- EEG Analysis2▲ 40×1 topic
- Immune Response2▲ 6.9×4 topics
- Cancer Genomics2▲ 51×1 topic
- Mutational Signatures2▲ 51×1 topic
- Clinical Characteristics1▲ 26×1 topic
- Thrombosis1▲ 12×1 topic
- Cognitive Functions1▲ 42×2 topics
- Cortical Networks1▲ 50×1 topic
- Glycosylation1▲ 27×3 topics
- Neuronal Oscillations1▲ 41×2 topics
- Synchronization1▲ 25×2 topics
Which research topics does Adaptive Biotechnologies (United States) publish most on?
By volume in 2022–2025: Lymphoma Diagnosis and Treatment, Multiple Myeloma Research and Treatments, SARS-CoV-2 and COVID-19 Research and Chronic Lymphocytic Leukemia Research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 3 works
- 2 Multiple Myeloma Research and Treatments Hematology 2 works
- 3 SARS-CoV-2 and COVID-19 Research Infectious Diseases 2 works
- 4 Chronic Lymphocytic Leukemia Research Genetics 2 works
- 5 CAR-T cell therapy research Oncology 2 works
- 6 EEG and Brain-Computer Interfaces Cognitive Neuroscience 2 works
- 7 Cancer Genomics and Diagnostics Cancer Research 2 works
- 8 COVID-19 Clinical Research Studies Infectious Diseases 1 works
- 9 Neural dynamics and brain function Cognitive Neuroscience 1 works
- 10 vaccines and immunoinformatics approaches Molecular Biology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Adaptive Biotechnologies (United States)'s research output changed?
Output in 2018–2022 was 6% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Seattle
- University of Washington
- Seattle University
- Fred Hutch Cancer Center
- University of Washington Medical Center
- University of Washington Applied Physics Laboratory
- Seattle Children's Hospital
- Amazon (United States)
- Virginia Mason Medical Center
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.